Nivolumab (new indication: esophageal squamous cell carcinoma, PD-L1-expression ≥ 1%, 1st line in combination with platinum- and fluoropyrimidine-based chemotherapy)

Subject:

• Active Substance: Nivolumab
• Name: Opdivo^®
• Therapeutic area: Squamous cell carcinoma of the esophagus
• Pharmaceutical company: Bristol-Myers Squibb GmbH & Co. KGaA

Time table:

• Start: 01.05.2022
• Final decision by G-BA: 20.10.2022

Final decision:

• Indication for a considerable additional benefit